GSK Specialty Surge Masks Single-Arm Risk Across HBV Rectal ROS1 Bets

GSK Reports Strong Q3 2026 Performance and Key Approvals

GSK reported strong financial results for Q3 2026, with total sales reaching £8.9 billion, a 5% increase at CER. This growth was primarily driven by Specialty Medicines, which saw a 15% rise in sales to £3.9 billion, alongside a 5% increase in core operating profit and 1% in core EPS. The quarter also marked significant pipeline progress and regulatory approvals, including Hibsago in the US and Japan for chronic hepatitis B, and Jemperli in the US for dMMR/MSI-H locally advanced rectal cancer. Positive registrational data for Jideytro in first-line ROS1-positive non-small cell lung cancer was also announced. GSK reaffirmed its 2026 guidance for turnover, core operating profit, and core EPS growth, and remains on track to initiate 22 Phase III trials this year.

• Financial Strength and Growth Drivers: GSK demonstrated robust financial performance in Q3 2026, with total sales climbing to £8.9 billion, reflecting a 5% increase at CER. This was significantly propelled by Specialty Medicines, which grew 15% to £3.9 billion, and strong contributions from HIV, Respiratory, Immunology & Inflammation, and Oncology segments. Core operating profit increased by 5% and core EPS by 1%, underscoring efficient operations and favorable product mix despite increased R&D investment.
• Key Regulatory Approvals: The quarter saw critical regulatory successes, notably the approval of Hibsago in both the US and Japan for chronic hepatitis B, hailed for its potential to redefine treatment with unprecedented functional cure rates. Additionally, Jemperli received US approval as the first immunotherapy for adults with dMMR/MSI-H locally advanced rectal cancer, marking a significant advancement in oncology.
• Advancing Pipeline and Future Outlook: GSK's pipeline continued to progress with positive registrational data for Jideytro in first-line ROS1-positive non-small cell lung cancer and promising early-phase data for Ris-Rez and Mo-Rez in lung and ovarian cancers, respectively. The company initiated a Phase III trial for its mRNA seasonal influenza vaccine and remains on track to commence 22 Phase III trials in 2026, reinforcing its commitment to innovation and future growth.
• Strategic Guidance and Shareholder Returns: GSK reaffirmed its 2026 guidance, projecting turnover growth of 3% to 5%, core operating profit growth of 7% to 9%, and core EPS growth of 7% to 9%. The company also maintained its ambitious 2031 sales outlook of over £40 billion and declared a Q3 2026 dividend of 17p, with an expected full-year dividend of 70p, signaling confidence in sustained performance and shareholder value.

Chronic Hepatitis B: A Landscape Ripe for Innovation

Long-term administration of nucleos(t)ide analogues (NA) has been the treatment of choice for chronic hepatitis B during the last decades. The NA has shown a good safety profile and high efficacy in controlling viral replication, improving histology, and decreasing the HCC incidence, decompensation, and mortality. However, the low probability of HBV surface antigen seroclearance made necessary an indefinite treatment. Nucleos(t)ide analogs provide durable suppression of hepatitis B virus (HBV) replication but rarely achieve hepatitis B surface antigen (HBsAg) loss, and interferon-based regimens are limited by modest efficacy and poor tolerability. Agreement among conference participants was reached that 'functional' but not sterilizing cure is achievable and should be defined as sustained HBsAg loss in addition to undetectable HBV DNA 6 months post-treatment. The primary endpoint of phase 3 trials should be functional cure; HBsAg loss in ≥30% of patients was suggested as an acceptable rate of response in these trials.

Fifty-nine children aged 3 to <18 years hepatitis B e antigen-positive with an HBV DNA titer >20,000 IU/mL and persistently normal alanine aminotransferase levels were randomized to 56 weeks of antiviral therapy with an oral nucleoside analogue [entecavir or lamivudine], combined with subcutaneous peginterferon alfa-2a from week 8, or 80 weeks of untreated observation. At 24 weeks post-treatment, 1 of 26 patients in the antiviral treatment group experienced HBsAg loss (vs none of 33 patients in the control group). No serious treatment-related adverse events were reported, and no patients discontinued treatment because of adverse events. A phase III clinical trial was conducted with a therapeutic vaccine containing two antigens of the hepatitis B virus (HBV; named NASVAC) in 78 patients with CHB expressing both HBV DNA and elevated levels of alanine aminotransferase (ALT) in the blood. Five years after the end of treatment (EOT), 60 NASVAC-recipient patients were enrolled in long-term follow-up. The levels of HBV DNA in the sera were reduced in 55 of the 60 patients, and 45 of them were negative for HBV DNA in the sera. ALT levels were also normalized in 40 of the 60 patients 5 years after EOT. In 279 patients who participated in two randomised controlled trials of peginterferon-based therapy, sustained response was achieved in 20.4% of patients. Among patients with an HBV RNA response (n = 135), 56.4% did not experience >0.5 log HBsAg decline. Among HBV RNA responders, sustained response was achieved in 47.6% of those with >1 log HBsAg decline (n = 20/42), vs 16.0% with <0.5 log decline (n = 12/75, P = 0.001).

Recent advances highlight the promise of RNA-targeting agents, including small interfering RNAs, antisense oligonucleotides, and RNA destabilizers, which directly reduce viral transcripts and antigen production. In parallel, immunomodulators such as pegylated interferon, checkpoint inhibitors, and therapeutic vaccines aim to restore HBV-specific immunity. Emerging evidence shows that rationally designed combination regimens, integrating nucleos(t)ide analogs as a backbone with antigen-lowering agents and immunotherapies, can synergistically enhance functional cure rates. Quantitative HBsAg reflects both covalently closed circular DNA and integrated HBV DNA activity, whereas hepatitis B core-related antigens (HBcrAgs) provide complementary information on covalently closed circular DNA transcriptional activity. Together, these markers enable more precise assessment of treatment response, prediction of relapse risk, and evaluation of long-term outcomes.

Overcoming Current Limitations in Chronic Hepatitis B Treatment

Current therapies for chronic hepatitis B (CHB) suppress hepatitis B virus (HBV) DNA replication but rarely achieve functional cure, defined as the loss of hepatitis B surface antigen (HBsAg) and suppression of HBV DNA to undetectable levels. CHB remains a significant global health challenge, affecting more than 250 million individuals worldwide, with persistence of covalently closed circular DNA and integrated HBV genome limiting complete eradication.

• Low rates of HBsAg loss with prolonged therapy: HBsAg seroclearance occurring in only 3%-5% of patients after 10 years of nucleos(t)ide analogs (NAs) therapy and 8%-14% within 3-5 years of pegylated interferon treatment. Predicted median time to HBsAg loss was 36 years for HBeAg-positive and 39 years for HBeAg-negative patients with virological response to ETV or TDF.

• Virologic persistence and immune barriers: HBV DNA integration, persistence of covalently closed circular DNA, and impaired immune responses present substantial barriers to HBsAg clearance, including insufficient B cell responses and compromised T cell function.

• High relapse and flare risk after NA withdrawal: Stopping NA therapy often leads to viral relapse and therefore life-long therapy is usually required. Seventy-two weeks after NA withdrawal, 23/45 (51%) patients had developed >5× ULN and 14 (31%) >20× ULN, with median time to develop ALT >5× ULN was 12 weeks after NA withdrawal.

• Limited durability and tolerability of interferon-based therapy: Sustained response to interferon alone is achieved only in a minority of patients, and side effects are common, which limit its clinical use. Over 10 % of patients still experience relapse, mostly within 48 weeks after functional cure.

• Class and agent-specific safety signals with oral NAs: All NAs carry a "Black Box" warning because of the potential risk for mitochondrial dysfunction, with class adverse effects (i.e., myopathy, neuropathy, lactic acidosis). Adefovir can lead to dose- and time-dependent nephrotoxicity, even at low doses, while tenofovir has significant renal and bone toxicity in patients with human immunodeficiency virus (HIV) infection.

Benchmarking Outcomes: Current Therapies for Chronic Hepatitis B

Long-term entecavir or tenofovir therapy in chronic hepatitis B achieves high rates of viral suppression with low resistance and excellent overall and liver-related survival. Functional cure remains infrequent on nucleos(t)ide analogue monotherapy, with higher rates reported for combination with peginterferon alfa-2b.

GSK's Specialty Surge: Redefining Care in Oncology and Chronic HBV

GSK's recent financial performance, buoyed by a robust 15% increase in Specialty Medicines sales, reflects a strategic pivot towards high-impact therapeutic areas. This growth is not merely financial; it signals a profound shift in treatment paradigms across oncology and infectious diseases, driven by key pipeline advancements and regulatory successes.

The approval of Hibsago for chronic hepatitis B (CHB) marks a significant milestone. For decades, CHB management has focused on viral suppression, but the advent of novel antisense oligonucleotides (ASOs) like Hibsago offers the potential for a functional cure – a sustained loss of hepatitis B surface antigen (HBsAg) and undetectable HBV DNA post-treatment. This represents a transformative leap for millions globally, moving beyond lifelong therapy to a potential resolution of the disease. However, the experience with similar ASOs suggests that clinicians will need to carefully monitor for treatment-related adverse events, such as transient but sometimes significant liver enzyme elevations, to ensure patient safety and adherence.

In oncology, Jemperli's US approval for dMMR/MSI-H locally advanced rectal cancer is equally groundbreaking. This specific patient population exhibits exceptional responses to PD-1 blockade, with studies demonstrating high pathological complete response rates. This opens the door to organ preservation strategies, allowing selected patients to potentially avoid radical surgery and its associated morbidities. This shift from a 'surgery-first' approach to a 'response-adaptive' strategy, where immunotherapy plays a central role in achieving non-operative management, is a testament to precision oncology. Yet, the successful implementation of such strategies demands highly specialized multidisciplinary teams and rigorous patient selection, alongside robust long-term surveillance protocols to ensure durable outcomes.

Furthermore, the positive registrational data for Jideytro in first-line ROS1-positive non-small cell lung cancer (NSCLC) positions it as a formidable contender in a competitive landscape. Next-generation ROS1 inhibitors like Jideytro are designed to overcome the limitations of earlier therapies, offering superior intracranial activity and efficacy against common resistance mutations. This promises to extend progression-free survival and improve quality of life for patients with this rare but aggressive lung cancer subtype. While highly effective, the challenge of acquired resistance remains, necessitating ongoing research into optimal sequencing and combination therapies to maintain long-term disease control. GSK's commitment to initiating 22 Phase III trials this year further solidifies its ambition to continue delivering innovative solutions that redefine patient care.